According to Eda Cengiz, MD, MHS, FAAP, associate professor of pediatrics at Yale School of Medicine, diabetes management technology is just beginning and can have a positive impact on the daily lives of diabetes patients.
According to Eda Cengiz, MD, MHS, FAAP, associate professor of pediatrics at Yale School of Medicine, diabetes management technology is just beginning and can have a positive impact on the daily lives of diabetes patients.
Transcript (slightly modified)
What’s your outlook on the future of diabetes management technology, including artificial pancreas systems?
This is the beginning of a digital revolution, a diabetes technology revolution, and I think we should be open to this.
When we have 70% to 80% of our patients in poor control, we cannot afford to wait. It’s our duty as clinicians to look for alternative tools to improve diabetes care. No matter what the reason is, people say it’s the compliance or some other issues that result in poor control, it’s our duty to find and implement new tools that our patients will benefit from.
I think a lot of people will like the system but they have to be realistic. This is not the perfect, full, automated, artificial pancreas system. They have to be patient and they have to learn the system and then once they get used to it, once we incorporate new technology and advances into the system, I think they are going to like it better and better. They are going to sleep better, they are going to feel better, they can exercise without any worries, and hopefully it will be the perfect system that will improve our outcomes until we have a cure.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Reveals Link Between Ovarian Cancer, Subsequent Dry Eye Disease Incidence
May 13th 2024Patients diagnosed with ovarian cancer (OC), particularly those older than 60 years or with a disease duration exceeding 5 years, had a higher incidence of subsequent dry eye disease (DED), suggesting a potential correlation between OC and DED.
Read More
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
Research Shows Prior Authorization Denials Delay Critical Immunology Care
May 10th 2024Results featured at the Academy of Managed Care Pharmacy 2024 annual meeting revealed a pattern of prior authorization rejections that could delay necessary therapeutic treatments for various patient groups.
Read More